Patents by Inventor Thomas Pietschmann
Thomas Pietschmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952631Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.Type: GrantFiled: October 9, 2018Date of Patent: April 9, 2024Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDENInventors: Daniel Todt, Sibylle Haid, Martin Wetzke, Gesine Hansen, Chris Lauber, Lars Kaderali, Thomas Pietschmann
-
Publication number: 20240091214Abstract: The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.Type: ApplicationFiled: January 21, 2022Publication date: March 21, 2024Applicants: TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Svenja SAKE, Sibylle HAID, Jessica RÜCKERT, Thomas SCHULZ, Thomas PIETSCHMANN
-
Patent number: 11602135Abstract: The present invention pertains to a non-human genetically modified animal with increased susceptibility to infection with a human virus. The invention suggests to genetically impair the expression of newly identified viral infection repression factors CD302, Cr11, Ndufc2, AW112010, Scarb2 and Zc3hav1, which markedly improves infection with human viruses in none-human hosts. Furthermore provided are methods for the generation of the animal of the invention, methods for increasing or reducing the susceptibility of a cell to viral infection, methods for screening novel modulators of viral infection as well as new therapy options for the treatment of viral diseases, in particular hepatitis C.Type: GrantFiled: June 1, 2017Date of Patent: March 14, 2023Assignee: TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBHInventors: Thomas Pietschmann, Richard Brown
-
Patent number: 11331371Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: GrantFiled: October 28, 2019Date of Patent: May 17, 2022Assignees: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Publication number: 20220024879Abstract: In a first aspect, the present invention relates to new compounds based on diphenylpiperazine and diphenylpiperidine structures. In particular, the present invention provides new flunarizine derivatives having improved hepaci virus infection inhibitory activity. In a further aspect, the present invention relates to a pharmaceutical composition containing said compound as well as the use of said pharmaceutical composition and the compounds according to the present invention in preventing or treating hepaci virus infection, in particular, HCV virus infection, like HCV of genotype 2. Moreover, a method for determining effectiveness of prophylactic or therapeutic treatment of hepaci virus, like HCV infection as well as a method for determining the therapy regimen of an individual afflicted with hepaci vims infection including HCV infection is provided. Said method is based on determining the sequence or interfacial hydrophobicity of the hepaci virus E1 protein.Type: ApplicationFiled: December 17, 2019Publication date: January 27, 2022Inventors: Thomas PIETSCHMANN, Dominic BANDA, Wladimir SOLODENKO
-
Publication number: 20200283848Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.Type: ApplicationFiled: October 9, 2018Publication date: September 10, 2020Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDENInventors: Daniel TODT, Sibylle HAID, Martin WETZKE, Gesine HANSEN, Chris LAUBER, Lars KADERALI, Thomas PIETSCHMANN
-
Publication number: 20200093888Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: ApplicationFiled: October 28, 2019Publication date: March 26, 2020Applicants: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Publication number: 20190297860Abstract: The present invention pertains to a non-human genetically modified animal with increased susceptibility to infection with a human virus. The invention suggests to genetically impair the expression of newly identified viral infection repression factors CD302, Cr11, Ndufc2, AW112010, Scarb2 and Zc3hav1, which markedly improves infection with human viruses in none-human hosts. Furthermore provided are methods for the generation of the animal of the invention, methods for increasing or reducing the susceptibility of a cell to viral infection, methods for screening novel modulators of viral infection as well as new therapy options for the treatment of viral diseases, in particular hepatitis C.Type: ApplicationFiled: June 1, 2017Publication date: October 3, 2019Inventors: Thomas PIETSCHMANN, Richard BROWN
-
Publication number: 20190046604Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: ApplicationFiled: November 18, 2016Publication date: February 14, 2019Applicants: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Publication number: 20150056166Abstract: The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection, and to a method of preventing or treating these infections.Type: ApplicationFiled: March 22, 2013Publication date: February 26, 2015Inventors: Thomas Pietschmann, Sibylle Haid, Juliane Gentzsch, Christina Grethe, Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Mourad Elhabiri, Xavier Benlloch-Martin
-
Publication number: 20140256618Abstract: The present invention describes new compounds (e.g.Type: ApplicationFiled: February 17, 2012Publication date: September 11, 2014Applicants: Twincore Zentrum Fuer Experimentelle und Klinische Infektionsforschung GmbH, HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Thomas Pietschmann, Juliane Drobnik, Heinrich Steinmetz, Brigitte Kunze
-
Publication number: 20130209403Abstract: The invention relates to Phospholipase A2 (hereinafter also referred to as PLA2) inhibitors for use in the treatment or prevention of flavivirus infection, in particular an infection with a flavivirus of the genus Flavi or the genus Hepaci. The invention also provides a pharmaceutical formulation for use in the treatment or prevention of an infection with a flavivirus of the genus Flavi or the genus Hepaci and a method of preventing or treating an infection with a flavivirus of the genus Flavi or the genus Hepaci.Type: ApplicationFiled: September 8, 2011Publication date: August 15, 2013Applicants: Ruprecht-Karls-Universitaet, Twincore Zentrum fuer Experimentelle and Klinische Infektionsforschung GmbHInventors: Nicolas Menzel, Thomas Pietschmann, Ralf Bartenschlager, Wolfgang Fischl